Biosyngen's BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma
SINGAPORE, July 16, 2024 /PRNewswire/ — Biosyngen, a leading biotechnology company focused…